Trinity Biotech

Trinity Biotech Long-term Debt

The Long-Term Debt of Trinity Biotech (TRIB) as of Oct 17, 2026 is 16.33 M USD. In the previous year, Long-Term Debt was 87.79 M USD — a change of -81.40% (lower).

Long-term Debt

16.33 MUSD

YoY

-81.40%

Last updated:

Long-Term Debt of Trinity Biotech is 2025 16.33 M USD. Long-Term Debt of Trinity Biotech was 2024 87.79 M USD. It decreases by -81.40% lower compared to the previous year.

The Trinity Biotech Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2017
94.83 M USD
Jan 1, 2018
81.62 M USD
Jan 1, 2019
99.77 M USD
Jan 1, 2020
83.88 M USD
Jan 1, 2022
58.05 M USD
Jan 1, 2023
54.65 M USD
Jan 1, 2024
87.79 M USD
Jan 1, 2025
16.33 M USD
The Trinity Biotech Long-term Debt history
YEARLong-term DebtYoY
16.33 MUSD-81.40%
87.79 MUSD+60.64%
54.65 MUSD-5.85%
58.05 MUSD-30.80%
83.88 MUSD-15.92%
99.77 MUSD+22.23%
81.62 MUSD-13.93%
94.83 MUSD-1.73%
96.49 MUSD+5.44%
91.51 MUSD+3,761.35%
2.37 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Long-Term Debt of Trinity Biotech is 16.33 M USD in 2025.

Long-Term Debt of Trinity Biotech changed from 87.79 M USD to 16.33 M USD, representing a -81.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech